S&P 500   4,075.78 (+0.62%)
DOW   33,044.20 (+0.56%)
QQQ   317.92 (+0.71%)
AAPL   162.80 (+0.27%)
MSFT   283.67 (-0.13%)
META   210.26 (+1.16%)
GOOGL   102.99 (+2.08%)
AMZN   102.92 (+0.90%)
TSLA   200.39 (+2.62%)
NVDA   274.71 (+0.32%)
NIO   10.53 (+0.67%)
BABA   102.42 (-0.93%)
AMD   96.89 (-1.01%)
T   19.09 (+0.05%)
F   12.45 (+1.30%)
MU   61.33 (-2.79%)
CGC   1.78 (+0.85%)
GE   94.73 (+0.72%)
DIS   98.83 (+0.74%)
AMC   4.96 (-0.20%)
PFE   40.56 (+0.45%)
PYPL   74.86 (+0.63%)
NFLX   340.95 (+0.74%)
S&P 500   4,075.78 (+0.62%)
DOW   33,044.20 (+0.56%)
QQQ   317.92 (+0.71%)
AAPL   162.80 (+0.27%)
MSFT   283.67 (-0.13%)
META   210.26 (+1.16%)
GOOGL   102.99 (+2.08%)
AMZN   102.92 (+0.90%)
TSLA   200.39 (+2.62%)
NVDA   274.71 (+0.32%)
NIO   10.53 (+0.67%)
BABA   102.42 (-0.93%)
AMD   96.89 (-1.01%)
T   19.09 (+0.05%)
F   12.45 (+1.30%)
MU   61.33 (-2.79%)
CGC   1.78 (+0.85%)
GE   94.73 (+0.72%)
DIS   98.83 (+0.74%)
AMC   4.96 (-0.20%)
PFE   40.56 (+0.45%)
PYPL   74.86 (+0.63%)
NFLX   340.95 (+0.74%)
S&P 500   4,075.78 (+0.62%)
DOW   33,044.20 (+0.56%)
QQQ   317.92 (+0.71%)
AAPL   162.80 (+0.27%)
MSFT   283.67 (-0.13%)
META   210.26 (+1.16%)
GOOGL   102.99 (+2.08%)
AMZN   102.92 (+0.90%)
TSLA   200.39 (+2.62%)
NVDA   274.71 (+0.32%)
NIO   10.53 (+0.67%)
BABA   102.42 (-0.93%)
AMD   96.89 (-1.01%)
T   19.09 (+0.05%)
F   12.45 (+1.30%)
MU   61.33 (-2.79%)
CGC   1.78 (+0.85%)
GE   94.73 (+0.72%)
DIS   98.83 (+0.74%)
AMC   4.96 (-0.20%)
PFE   40.56 (+0.45%)
PYPL   74.86 (+0.63%)
NFLX   340.95 (+0.74%)
S&P 500   4,075.78 (+0.62%)
DOW   33,044.20 (+0.56%)
QQQ   317.92 (+0.71%)
AAPL   162.80 (+0.27%)
MSFT   283.67 (-0.13%)
META   210.26 (+1.16%)
GOOGL   102.99 (+2.08%)
AMZN   102.92 (+0.90%)
TSLA   200.39 (+2.62%)
NVDA   274.71 (+0.32%)
NIO   10.53 (+0.67%)
BABA   102.42 (-0.93%)
AMD   96.89 (-1.01%)
T   19.09 (+0.05%)
F   12.45 (+1.30%)
MU   61.33 (-2.79%)
CGC   1.78 (+0.85%)
GE   94.73 (+0.72%)
DIS   98.83 (+0.74%)
AMC   4.96 (-0.20%)
PFE   40.56 (+0.45%)
PYPL   74.86 (+0.63%)
NFLX   340.95 (+0.74%)
NASDAQ:KLDO

Kaleido Biosciences - KLDO Stock Forecast, Price & News

$0.0002
0.00 (0.00%)
(As of 03/31/2023 09:30 AM ET)
Add
Compare
Today's Range
$0.0002
$0.0002
50-Day Range
N/A
52-Week Range
$0.00
$0.14
Volume
156 shs
Average Volume
12,712 shs
Market Capitalization
$8,524.60
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.70

Kaleido Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
849,900.0% Upside
$1.70 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Kaleido Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.27) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars


KLDO stock logo

About Kaleido Biosciences (NASDAQ:KLDO) Stock

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

KLDO Kaleido Biosciences, Inc.
Adam Mesh: “This Strategy Saved My Trading Career”
Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. pixel
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Kaleido Biosciences, Inc. (KLDO)
ATER, HNRG and AGLE among mid-day movers
Kaleido Biosciences shuts down
Radius Health Announces Leadership Appointments
See More Headlines
Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Company Calendar

Last Earnings
11/01/2021
Today
3/31/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.70
High Stock Price Forecast
$1.70
Low Stock Price Forecast
$1.70
Forecasted Upside/Downside
+849,900.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million

Miscellaneous

Free Float
38,787,000
Market Cap
$8,524.60
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Kimberly Hocknell
    Senior Vice President-Technical Operations













KLDO Stock - Frequently Asked Questions

Should I buy or sell Kaleido Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KLDO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KLDO, but not buy additional shares or sell existing shares.
View KLDO analyst ratings
or view top-rated stocks.

What is Kaleido Biosciences' stock price forecast for 2023?

1 analysts have issued twelve-month price targets for Kaleido Biosciences' stock. Their KLDO share price forecasts range from $1.70 to $1.70. On average, they anticipate the company's share price to reach $1.70 in the next twelve months. This suggests a possible upside of 849,900.0% from the stock's current price.
View analysts price targets for KLDO
or view top-rated stocks among Wall Street analysts.

How have KLDO shares performed in 2023?

Kaleido Biosciences' stock was trading at $0.0005 on January 1st, 2023. Since then, KLDO shares have decreased by 60.0% and is now trading at $0.0002.
View the best growth stocks for 2023 here
.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $0.00.

How much money does Kaleido Biosciences make?

Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $8,524.60 and generates $1.10 million in revenue each year.

How can I contact Kaleido Biosciences?

The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000.

This page (NASDAQ:KLDO) was last updated on 3/31/2023 by MarketBeat.com Staff